A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy

Immunological Reviews

Volumn 194, Issue , 2003, Pages 105-111

  Bataille, Regis ^a,b   Robillard, Nelly ^a   Pellat Deceunynck, Catherine ^a   Amiot, Martine ^a  

^a INSERM   (France)

^b INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; INSULIN; INTERLEUKIN 6; SOMATOMEDIN C;

ANTIGEN EXPRESSION; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL PROLIFERATION; CELL RENEWAL; CHROMOSOME 14Q; CLONOGENESIS; DISEASE MODEL; HUMAN; HUMAN CELL; MYELOMA CELL; PHENOTYPE; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TARGET CELL;

ANIMALS; ANTIGENS, CD45; CELL DIFFERENTIATION; CELL DIVISION; HUMANS; MULTIPLE MYELOMA; PLASMA CELLS; SIGNAL TRANSDUCTION;

EID: 0038336720     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00039.x     Document Type: Review

References (39)

1. Bataille R, Harrousseau JL. Multiple myeloma. Recent advances in the biology and management. New Engl J Med 1997;336:1657-1664.
2. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
3. Kuel WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-187.
4. Greipp PR, Witzig TE, Habermann TM, Katzmann JA, O'Fallon WM, Kyle RA. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987;62:969-977.
5. Drewinko B, Alexanian R, Boyer H, Barlogie B, Rubinow SI. The growth fraction of human myeloma cells. Blood 1981;57:333-338.
6. Charbonneau H, Tonks NK, Walsh KA, Fischer EH. The leukocyte common antigen (CD 45): a putative receptor-linked protein tyrosine phosphatase. Proc Natl Acad Sci USA 1988;85:7182-7186.
7. ras activation in B cells stimulated through the antigen receptor. J Immunol 1994;152:3306-3316.
8. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 2003;21:107-137.
9. + monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 1991;78:711-719.
10. Medina F, Segundo C, Campos-Caro A, Gonzalez-Garcia I, Brieva JA. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 2002;99:2154-2161.
11. Terstappen LWMM, Johnsen S, Segers-Nolten I MJ, Loken MR. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 1990;76:1739-1747.
12. Harada Y, et al. Identification of early plasma cells in peripheral blood and their clinical significance. Br J Haematol 1996;92:184-191.
13. Ocqueteau M, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Am J Pathol 1998;152:1655-1665.
14. Jego G, et al. Reactive plasmocytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999;94:701-712.
15. Joshua D, Petersen A, Brown R, Pope B, Snowdon L, Gibson J. The labelling index of primitive cells determines the clinical behaviour of patients with myelomatosis. Br J Haematol 1996;94:76-81.
16. - immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol 1999;105:131-140.
17. Rawstron AC, et al. In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression. Br J Haematol 2001;115:794-802.
18. Jackson N, Ling NR, Ball JJ, Bromidge E, Nathan PD, Franklin IM. An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation Antigens. Clin Exp Immunol 1988;72:351-356.
19. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 1993;81:3357-3364.
20. Witzig TE, Kimlinger TK, Gregory J, Ahmann J, Katzmann JA, Greipp PR. Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 1996;26:113-120.
21. Schneider U, Van Lessen A, Huhn D, Serke S. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br J Haematol 1997;97:56-64.
22. Rawstron AC, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 1997;97:46-55.
23. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999;94:3576-3582.
24. Asosing K, et al. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells. Exp Hematol 2001;29:77-84.
25. Asosingh K, Menu E, Van Valckenborgh E, Van Camp B, Vanderkerken K. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine model of myeloma. Clin Exp Metastasis 2002;19:583-591.
26. Asosingh K, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. Multiple myeloma progression in the 5T2 murine model is a multi-stage and dynamic process of differentiation, proliferation, invasion and apoptosis. Blood in press.
27. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001;97:1817-1822.
28. Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 1995;85:487-494.
29. Kawano M, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1998;332:83-85.
30. Klein B, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-526.
31. Mahmoud MS, Ishikawa H, Fujii R, Kawano MM. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood 1988;92:3887-3897.
32. Ishikawa H, Mahmoud MS, Fujii R, Abroun S, Kawano MM. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma. Leuk Lymphoma 2000;39:51-55.
33. Kawano MM, et al. Growth mechanism of human myeloma cells by interleukin-6. Int J Hematol 2002;76:329-333.
34. Zhang XG, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994;83:3654-3663.
35. Ishikawa H, et al. Requirements of src family kinase activity associated with CD45 for myeloma cells proliferation by interleukin-6. Blood 2002;99:2172-2176.
36. Irie-Sasaki J, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 2001;409:349-354.
37. Kulas DT, Freund GG, Mooney RA. The transmembrane protein-tyrosine phosphatase CD45 is associated with decreased insulin receptor signaling. J Biol Chem 1996;271:755-760.
38. Jelinek D, Witzig T, Arendt B. A role for insulin-like growth factor in the regulation of IL-6 responsive human myeloma cell line growth. J Immunol 1997;159:487-496.
39. Kulas D, Zhang WR, Goldstein BJ, Furlanetto RW, Mooney RA. Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR. J Biol Chem 1995;270:2435-2438.